Phospho-Ser358 Eukaryotic Elongation Factor 1 alpha 2 (eEF1A2) Antibody
Affinity purified rabbit polyclonal antibody
- CITATIONS: 1
|Predicted||Human, Rat, Monkey, Chicken, Xenopus|
|Calculated MW||50 KDa|
|Other Names||Elongation factor 1-alpha 2, EF-1-alpha-2, Eukaryotic elongation factor 1 A-2, eEF1A-2, Statin-S1, EEF1A2, EEF1AL, STN|
|Target/Specificity||Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser358 conjugated to KLH.|
|Format||Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.|
|Antibody Specificity||Specific for the ~50k eEF1A2 phosphorylated at Ser358. Immunolabeling of the eEF1A2 band is blocked by the treatment of the lysate with lambda phosphatase (30 minutes, 800 units / 1 mg protein).|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-Ser358 Eukaryotic Elongation Factor 1 alpha 2 (eEF1A2) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Provided below are standard protocols that you may find useful for product applications.
Eukaryotic Elongation Factor eEF1A exists in two variant forms, eEF1A1 and eEF1A2. While eEF1A1 is almost ubiquitously expressed in humans, eEF1A2 is predominantly found in heart, brain, and skeletal muscle (Knudsen et al., 1993). Expression of eEF1A2 may have a role in ovarian cancer, as its expression is drastically increased in human ovarian tumors (Anand et al., 2002). Due to differences in structural models between the two isoforms, eEF1A1 and eEF1A2 likely have variant-specific phosphorylation sites (Soares et al., 2009). Ribosome-associated JNK phosphorylates Ser358 on eEF1A2 to promote degradation of newly synthesized polypeptides by the proteasome (Gandin et al., 2013).
Knudsen SM, Frydenberg J, Clark BF, Leffers H. Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterization of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem. 1993;215:549-554.
Anand N, Murphy s, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet. 2002;31:301-305.
Soares DC, Barlow PN, Newbery HJ, Porteous DJ, Abbot CM. Structural models of human eEF1A1 and eEF1A2 reveal two distant surface clusters of sequence variation and potential differences in phosphorylation. PLoS One. 2009 Jul 28;4(7):e6315.
Gandin V, Gutierrez GJ, Brill LM, Varsano T, Feng Y, Aza-Blanc P, Au Q, McLaughlan S, Ferreira TA, Alain T, Sonenberg N, Topisirovic I, Ronai ZA. Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-Terminal Kinase/Eukaryotic Elongation Factor 1A2 complex. 2013 Jul;33(13):2510-26.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.